Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choo, Eun Ju | - |
dc.contributor.author | Chambers, Henry F. | - |
dc.date.accessioned | 2021-08-11T16:44:09Z | - |
dc.date.available | 2021-08-11T16:44:09Z | - |
dc.date.issued | 2016-12 | - |
dc.identifier.issn | 2093-2340 | - |
dc.identifier.issn | 2092-6448 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8567 | - |
dc.description.abstract | Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of health care-associated infections. Vancomycin remains an acceptable treatment option. There has been a welcome increase in the number of agents available for the treatment of MRSA infection. These drugs have certain differentiating attributes and may offer some advantages over vancomycin, but they also have significant limitations. These agents provide some alternative when no other options are available. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy | - |
dc.title | Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3947/ic.2016.48.4.267 | - |
dc.identifier.scopusid | 2-s2.0-85009968766 | - |
dc.identifier.wosid | 000392946500002 | - |
dc.identifier.bibliographicCitation | Infection and Chemotherapy, v.48, no.4, pp 267 - 273 | - |
dc.citation.title | Infection and Chemotherapy | - |
dc.citation.volume | 48 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 267 | - |
dc.citation.endPage | 273 | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002188292 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.subject.keywordPlus | MINIMUM INHIBITORY CONCENTRATION | - |
dc.subject.keywordPlus | BLOOD-STREAM INFECTIONS | - |
dc.subject.keywordPlus | RANDOMIZED PHASE-2 TRIAL | - |
dc.subject.keywordPlus | SALVAGE THERAPY | - |
dc.subject.keywordPlus | CLINICAL-EFFICACY | - |
dc.subject.keywordPlus | STANDARD THERAPY | - |
dc.subject.keywordPlus | RABBIT MODEL | - |
dc.subject.keywordPlus | VANCOMYCIN | - |
dc.subject.keywordPlus | DAPTOMYCIN | - |
dc.subject.keywordPlus | CEFTAROLINE | - |
dc.subject.keywordAuthor | Methicillin-resistant Staphylcoccus aureus | - |
dc.subject.keywordAuthor | Vancomycin | - |
dc.subject.keywordAuthor | Treatment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.